MM-10001 is under clinical development by GlycaNova and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect MM-10001’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 12 Aug 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MM-10001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
MM-10001 (beta-glucan) is under development for the treatment of advanced or metastatic non-small cell lung cancer. The drug candidate is administered orally. MM-10001 is a bioactive agent exported from Shitake Mycelium in the aqueous medium. It acts by targeting cd11b.
GlycaNova is a developer, manufacturer and distributor of nutraceuticals and active pharmaceutical ingredients. The company offers nutraceutical products such as ganodex, immuna, lentinanxp, lentinex and lentiguard. It also provides products for cancers, liver diseases, diabetes, allergies, AIDS, skin diseases, elevated blood pressure, elevated cholesterol, chronic bronchitis, phlebitis and thrombosis. GlycaNova develops products based on the immunologically active substances. The company conducts a clinical trial on drug candidate MM-10-001, used in treatment of cancer. It offers natural health products in the form of dietary supplements and functional food ingredients. GlycaNova is headquartered in Fredrikstad, Oslo, Norway.
Quick View MM-10001 LOA Data
|Highest Development Stage|